Back to top
more

CytomX Therapeutics (CTMX)

(Delayed Data from NSDQ)

$2.10 USD

2.10
2,651,263

-0.07 (-3.23%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $2.10 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

by Zacks Equity Research

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.

Zacks Equity Research

Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why

by Zacks Equity Research

Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.

Zacks Equity Research

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.

Zacks Equity Research

Here's Why Investors May Bet on BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.

Zacks Equity Research

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

by Zacks Equity Research

Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.

Zacks Equity Research

Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi

by Zacks Equity Research

Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.

Zacks Equity Research

Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

by Zacks Equity Research

Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.

Zacks Equity Research

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

by Zacks Equity Research

Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.

Zacks Equity Research

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging. However, pipeline setback remains a concern.

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

by Zacks Equity Research

Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.

Zacks Equity Research

Edgewise (EWTX) Rallies 35% on Issue of New Common Stock

by Zacks Equity Research

Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.

Zacks Equity Research

Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates

by Zacks Equity Research

The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.

Zacks Equity Research

TransCode (RNAZ) Down 50% on Issue of New Common Stock

by Zacks Equity Research

TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.

Zacks Equity Research

ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why

by Zacks Equity Research

ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.

Zacks Equity Research

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug

by Zacks Equity Research

Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.

Zacks Equity Research

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

by Zacks Equity Research

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.

Zacks Equity Research

Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.

Zacks Equity Research

MAIA Soars 20% on Interim Results From Lung Cancer Study

by Zacks Equity Research

MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.

Zacks Equity Research

Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

by Zacks Equity Research

Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.

Zacks Equity Research

Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.

Zacks Equity Research

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

by Zacks Equity Research

Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.

Zacks Equity Research

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

by Zacks Equity Research

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.

Zacks Equity Research

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Zacks Equity Research

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

by Zacks Equity Research

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

Zacks Equity Research

Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

by Zacks Equity Research

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.